Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05481125 · ClinicalTrials.gov registry record · NA

Clareon Toric vs Eyhance Toric

A NA study of Cataract and Aphakia, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
203
Enrollment target
8
Study locations

NCT05481125 is a NA study of Cataract and Aphakia that has completed, run by Alcon Research. The registered enrollment target is 203 participants, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (10% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05481125, a NA study of Cataract and Aphakia, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
203 participants
Enrollment target
8
Study locations

Study Summary

The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

Conditions Studied

Interventions

  • DEVICE Eyhance IOL
  • DEVICE Clareon IOL
  • DEVICE Clareon Toric IOL
  • DEVICE Eyhance Toric IOL
  • PROCEDURE Phacoemulsification surgery

Study Locations (8)

Texas

  • Houston Eye Associates - Houston
  • Berkeley Eye Center - Houston
  • Texas Eye Research Center - Hurst

New York

  • Seeta Eye Centers - Poughkeepsie

Ohio

  • Cleveland Eye Clinic - Brecksville

South Carolina

  • Carolina Eyecare Physicians, LLC - Mt. Pleasant

Tennessee

  • Vision for Life - Nashville

Utah

  • The Eye Institute of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2022-10-10
Est. Completion 2023-10-16
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT05481125

The ClinicalTrials.gov registry entry for NCT05481125 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (10% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 5 interventions - of which Eyhance IOL is the first listed.

NCT05481125 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT05481125 about?

NCT05481125 is a clinical study titled "Clareon Toric vs Eyhance Toric". The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

What is the current status of trial NCT05481125?

This trial is currently completed. It is a NA study. The enrollment target is 203 participants. The study started on 2022-10-10. Estimated completion is 2023-10-16.

What conditions does trial NCT05481125 study?

This clinical trial studies the following conditions: Cataract, Aphakia.

What interventions are being tested in trial NCT05481125?

The interventions under investigation include: Eyhance IOL (DEVICE), Clareon IOL (DEVICE), Clareon Toric IOL (DEVICE), Eyhance Toric IOL (DEVICE), Phacoemulsification surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05481125?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05481125 being conducted?

This trial has 8 study locations across New York, Ohio, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.